                         SEQUENCE LISTING

<110>  LBL BIOTECHNOLOGY INC.
 
<120>  COMBINATION THERAPY USING AN IL-20 ANTAGONIST AND AN IMMUNE 
       CHECKPOINT INHIBITOR

<130>  G4590-07700PCT

<150>  US 16/855,637
<151>  2020-04-22

<160>  13    

<170>  PatentIn version 3.5

<210>  1
<211>  363
<212>  DNA
<213>  Artificial sequence

<220>
<223>  Synthetic polynucleotide

<400>  1
gaattgaagc ttgaggagtc tggaggaggc ttggtgcagc ctggaggatc catgaaactc       60

tcttgtgctg cctctggatt cacttttagt gacgcctgga tggactgggt ccgccagtct      120

ccagagaagg ggcttgagtg gattgctgaa attagaagca aagctaataa ttatgcaaca      180

tactttgctg agtctgtgaa agggaggttc accatctcaa gagatgattc caaaagtggt      240

gtctacctgc aaatgaacaa cttaagagct gaggacactg gcatttattt ctgtaccaag      300

ttatcactac gttactggtt cttcgatgtc tggggcgcag ggaccacggt caccgtctcc      360

tca                                                                    363


<210>  2
<211>  121
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Synthetic polypeptide

<400>  2

Glu Leu Lys Leu Glu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 
1               5                   10                  15      


Ser Met Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp Ala 
            20                  25                  30          


Trp Met Asp Trp Val Arg Gln Ser Pro Glu Lys Gly Leu Glu Trp Ile 
        35                  40                  45              


Ala Glu Ile Arg Ser Lys Ala Asn Asn Tyr Ala Thr Tyr Phe Ala Glu 
    50                  55                  60                  


Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Gly 
65                  70                  75                  80  


Val Tyr Leu Gln Met Asn Asn Leu Arg Ala Glu Asp Thr Gly Ile Tyr 
                85                  90                  95      


Phe Cys Thr Lys Leu Ser Leu Arg Tyr Trp Phe Phe Asp Val Trp Gly 
            100                 105                 110         


Ala Gly Thr Thr Val Thr Val Ser Ser 
        115                 120     


<210>  3
<211>  339
<212>  DNA
<213>  Artificial sequence

<220>
<223>  Synthetic polynucleotide

<400>  3
gattttgtga tgacccagac tccactcact ttgtcggtta ccattggaca accagcctcc       60

atctcttgca agtcaagtca gagcctcttg gatagtgatg gaaagacata tttgaattgg      120

ttgttacaga ggccaggcca gtctccaaag cacctcatct atctggtgtc taaactggac      180

tctggagtcc ctgacaggtt cactggcagt ggatcaggga ccgatttcac actgagaatc      240

agcagagtgg aggctgagga tttgggagtt tattattgct ggcaaagtac acattttccg      300

tggacgttcg gtggaggcac caagctggaa atcaaacgg                             339


<210>  4
<211>  113
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Synthetic polypeptide

<400>  4

Asp Phe Val Met Thr Gln Thr Pro Leu Thr Leu Ser Val Thr Ile Gly 
1               5                   10                  15      


Gln Pro Ala Ser Ile Ser Cys Lys Ser Ser Gln Ser Leu Leu Asp Ser 
            20                  25                  30          


Asp Gly Lys Thr Tyr Leu Asn Trp Leu Leu Gln Arg Pro Gly Gln Ser 
        35                  40                  45              


Pro Lys His Leu Ile Tyr Leu Val Ser Lys Leu Asp Ser Gly Val Pro 
    50                  55                  60                  


Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Arg Ile 
65                  70                  75                  80  


Ser Arg Val Glu Ala Glu Asp Leu Gly Val Tyr Tyr Cys Trp Gln Ser 
                85                  90                  95      


Thr His Phe Pro Trp Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys 
            100                 105                 110         


Arg 
    


<210>  5
<211>  420
<212>  DNA
<213>  Artificial sequence

<220>
<223>   nucleotide sequence encoding the amino acid sequence of SEQ ID 
       NO:6

<400>  5
atgtacttgg gactgaacta tgttttcatc gtttttctcc tgaatggtgt ccagagtgaa       60

gtgcagcttg tggagtctgg aggaggcttg gtgcagcctg gaggatccct gaaactctct      120

tgtgctgcct ctggattcac ttttagtgac gcctggatgg actgggtccg ccaggcttcc      180

gggaaggggc ttgagtggat tgctgaaatt agaagcaaag ctaataatta tgcaacatac      240

tttgctgagt ctgtgaaagg gaggttcacc atctcaagag atgattccaa aaacaccgcc      300

tacctgcaaa tgaacagctt aaaaaccgag gacactgccg tttattactg taccaagtta      360

tcactgcgtt actggttctt cgatgtctgg ggccagggga ccctggtcac cgtctcctca      420


<210>  6
<211>  140
<212>  PRT
<213>  Artificial sequence

<220>
<223>  the amino acid sequence of the precursor VH chain variable region
       of exemplary humanized anti-IL-20 antibodies HL1 and HL2

<400>  6

Met Tyr Leu Gly Leu Asn Tyr Val Phe Ile Val Phe Leu Leu Asn Gly 
1               5                   10                  15      


Val Gln Ser Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln 
            20                  25                  30          


Pro Gly Gly Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe 
        35                  40                  45              


Ser Asp Ala Trp Met Asp Trp Val Arg Gln Ala Ser Gly Lys Gly Leu 
    50                  55                  60                  


Glu Trp Ile Ala Glu Ile Arg Ser Lys Ala Asn Asn Tyr Ala Thr Tyr 
65                  70                  75                  80  


Phe Ala Glu Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser 
                85                  90                  95      


Lys Asn Thr Ala Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr 
            100                 105                 110         


Ala Val Tyr Tyr Cys Thr Lys Leu Ser Leu Arg Tyr Trp Phe Phe Asp 
        115                 120                 125             


Val Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser 
    130                 135                 140 


<210>  7
<211>  363
<212>  DNA
<213>  Artificial sequence

<220>
<223>  the nucleotide sequence encoding the amino acid sequence of SEQ 
       ID NO:8

<400>  7
gaagtgcagc ttgtggagtc tggaggaggc ttggtgcagc ctggaggatc cctgaaactc       60

tcttgtgctg cctctggatt cacttttagt gacgcctgga tggactgggt ccgccaggct      120

tccgggaagg ggcttgagtg gattgctgaa attagaagca aagctaataa ttatgcaaca      180

tactttgctg agtctgtgaa agggaggttc accatctcaa gagatgattc caaaaacacc      240

gcctacctgc aaatgaacag cttaaaaacc gaggacactg ccgtttatta ctgtaccaag      300

ttatcactgc gttactggtt cttcgatgtc tggggccagg ggaccctggt caccgtctcc      360

tca                                                                    363


<210>  8
<211>  121
<212>  PRT
<213>  Artificial sequence

<220>
<223>  the amino acid sequence of the mature VH chain variable region 
       (which lacks the signal peptide) of the exemplary humanized 
       anti-IL-20 antibodies HL1 and HL2

<400>  8

Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 
1               5                   10                  15      


Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp Ala 
            20                  25                  30          


Trp Met Asp Trp Val Arg Gln Ala Ser Gly Lys Gly Leu Glu Trp Ile 
        35                  40                  45              


Ala Glu Ile Arg Ser Lys Ala Asn Asn Tyr Ala Thr Tyr Phe Ala Glu 
    50                  55                  60                  


Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr 
65                  70                  75                  80  


Ala Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr 
                85                  90                  95      


Tyr Cys Thr Lys Leu Ser Leu Arg Tyr Trp Phe Phe Asp Val Trp Gly 
            100                 105                 110         


Gln Gly Thr Leu Val Thr Val Ser Ser 
        115                 120     


<210>  9
<211>  396
<212>  DNA
<213>  Artificial sequence

<220>
<223>  the nucleotide sequence encoding the amino acid sequence of SEQ 
       ID NO:10

<400>  9
atgatgagtc ctgcccagtt cctgtttctg ttggtgctct ggattcggga aaccaacggt       60

gatatcgtga tgacccagac tccactctct ttgtccgtta cccctggaca accagcctcc      120

atctcttgca agtcaagtca gagcctcttg gatagtgatg gaaagacata tttgaattgg      180

ttgttacaga agccaggcca gtctccacag cacctcatct atctggtgtc taaactggac      240

tctggagtcc ctgacaggtt cagtggcagt ggatcaggga ccgatttcac actgaaaatc      300

agcagagtgg aggctgagga tgttggagtt tattattgct ggcaaagtac acattttccc      360

tggaccttcg gtggaggcac caaggtggaa atcaaa                                396


<210>  10
<211>  132
<212>  PRT
<213>  Artificial sequence

<220>
<223>  the amino acid sequence of the precursor VL chain variable region
       of exemplary humanized anti-IL-20 antibody HL2

<400>  10

Met Met Ser Pro Ala Gln Phe Leu Phe Leu Leu Val Leu Trp Ile Arg 
1               5                   10                  15      


Glu Thr Asn Gly Asp Ile Val Met Thr Gln Thr Pro Leu Ser Leu Ser 
            20                  25                  30          


Val Thr Pro Gly Gln Pro Ala Ser Ile Ser Cys Lys Ser Ser Gln Ser 
        35                  40                  45              


Leu Leu Asp Ser Asp Gly Lys Thr Tyr Leu Asn Trp Leu Leu Gln Lys 
    50                  55                  60                  


Pro Gly Gln Ser Pro Gln His Leu Ile Tyr Leu Val Ser Lys Leu Asp 
65                  70                  75                  80  


Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe 
                85                  90                  95      


Thr Leu Lys Ile Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr 
            100                 105                 110         


Cys Trp Gln Ser Thr His Phe Pro Trp Thr Phe Gly Gly Gly Thr Lys 
        115                 120                 125             


Val Glu Ile Lys 
    130         


<210>  11
<211>  336
<212>  DNA
<213>  Artificial sequence

<220>
<223>  the nucleotide sequence encoding the amino acid sequence of SEQ 
       ID NO:12

<400>  11
gatatcgtga tgacccagac tccactctct ttgtccgtta cccctggaca accagcctcc       60

atctcttgca agtcaagtca gagcctcttg gatagtgatg gaaagacata tttgaattgg      120

ttgttacaga agccaggcca gtctccacag cacctcatct atctggtgtc taaactggac      180

tctggagtcc ctgacaggtt cagtggcagt ggatcaggga ccgatttcac actgaaaatc      240

agcagagtgg aggctgagga tgttggagtt tattattgct ggcaaagtac acattttccc      300

tggaccttcg gtggaggcac caaggtggaa atcaaa                                336


<210>  12
<211>  112
<212>  PRT
<213>  Artificial sequence

<220>
<223>   the amino acid sequence of the mature VL chain variable region 
       (which lacks the signal peptide) of exemplary humanized 
       anti-IL-20 antibody HL2

<400>  12

Asp Ile Val Met Thr Gln Thr Pro Leu Ser Leu Ser Val Thr Pro Gly 
1               5                   10                  15      


Gln Pro Ala Ser Ile Ser Cys Lys Ser Ser Gln Ser Leu Leu Asp Ser 
            20                  25                  30          


Asp Gly Lys Thr Tyr Leu Asn Trp Leu Leu Gln Lys Pro Gly Gln Ser 
        35                  40                  45              


Pro Gln His Leu Ile Tyr Leu Val Ser Lys Leu Asp Ser Gly Val Pro 
    50                  55                  60                  


Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile 
65                  70                  75                  80  


Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Trp Gln Ser 
                85                  90                  95      


Thr His Phe Pro Trp Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys 
            100                 105                 110         


<210>  13
<211>  112
<212>  PRT
<213>  Artificial sequence

<220>
<223>  identical to the VL of HL2 except that the I residue at position 
       2 of mature VL of HL2 is replaced with F

<400>  13

Asp Phe Val Met Thr Gln Thr Pro Leu Ser Leu Ser Val Thr Pro Gly 
1               5                   10                  15      


Gln Pro Ala Ser Ile Ser Cys Lys Ser Ser Gln Ser Leu Leu Asp Ser 
            20                  25                  30          


Asp Gly Lys Thr Tyr Leu Asn Trp Leu Leu Gln Lys Pro Gly Gln Ser 
        35                  40                  45              


Pro Gln His Leu Ile Tyr Leu Val Ser Lys Leu Asp Ser Gly Val Pro 
    50                  55                  60                  


Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile 
65                  70                  75                  80  


Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Trp Gln Ser 
                85                  90                  95      


Thr His Phe Pro Trp Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys 
            100                 105                 110         


